Career Opportunities

We will be listing career opportunities amongst our network members, core facilities, and partnering organizations. Although we will keep this page updated on a bi-weekly basis, we cannot promise that job postings listed here are still available on the company website. Therefore, we recommend you click through to the posting linked out to the company’s website.

 

National Research Council Canada

 

Postdoctoral Fellowships

 

What is the program?

 

The NRC is excited to announce a new initiative to bring up to ten postdoctoral fellows (PDFs) to work alongside our internationally recognized research leaders. The program will offer PDFs access to unique world-class facilities and the opportunity to work alongside multi-disciplinary teams of expert researchers and technicians on projects of critical importance to Canada. PDFs will carry out research on innovative research projects, with opportunities for career development (publications and/or industry interaction).

 

PDFs will be offered appointments to the staff of the National Research Council on a term basis and will be offered salaries and benefits currently available to Research Officers. Salaries commensurate with experience are taxable and subject to other deductions. As a guide, the current annual PhD recruiting rate is $64,437. In addition PDFs will be allocated a travel fund to support their work.

 

Who is eligible?

 

  • Fellowships will be for two years contingent on satisfactory progress achieved during the first year.
  • Candidates should have obtained a PhD (or equivalent) within the past three years (PhD received on or after July 1, 2014) or expect to complete their PhD by September, 2017. To be eligible, a candidate will be required to submit their CV, three publications, a statement of interest for each project to which they wish to apply, and send the names of three references with contact information.
  • Fellows will work in a lab under the direct supervision of an NRC researcher.

 

Important dates

 

Applications are due by April 23, 2017 with awards announced by May 12, 2017. Successful fellows may commence their award anytime from July 1, 2017 to December 15, 2017.

 

Selection

 

Applications will be reviewed by the NRC PDF Steering Committee. The committee will consult with project sponsors to select candidates based on their academic excellence, qualification for the project, and their fit with their project supervisor.

 

Learn More

 

Auer Translational Research Lab at the Ottawa Hospital Research Institute

 

PhD and Postdoctoral fellows

 

Highly motivated PhD and Postdoctoral fellows are being sought to join the Auer Translational Research Lab at the Ottawa Hospital Research Institute to investigate the efficacy of novel immunotherapeutic strategies targeting immune dysfunction in abdominal cancers.

 

Research Program Overview:
 

An improved understanding of the immune systems role in combating cancer has resulted in the development of a number of clinically effective therapeutics. However, ongoing large-scale whole genome sequencing efforts continue to reveal the incredible genetic diversity present in patient tumours suggesting that personalized vaccine strategies aimed at enhancing immune recognition of patient-specific neoantigens may offer the best way forward. Dr Rebecca Auer’s research group is currently developing an autologous infected cell vaccine platform, based on the oncolytic virus (OV), Maraba, for the treatment of abdominal malignancies. Candidates are being sought to continue the preclinical development of this approach which combines the potent immune stimulating properties of OV delivery with patient specific antigens to overcome the immunosuppressive tumour microenvironment and promote effective anti-tumour immune responses.

 

This project is a collaboration with Dr. John Bell, a leader in the field of OV immunotherapy and Chief Scientific Officer of Turnstone Biologics, developing the Maraba virus platform. It is funded by two large program project grants, including an enabling grant designed to ensure that this therapy is optimized (including GMP manufacturing) for early phase clinical trials within 36 months. The lab has access to cancer surgical specimens and a GMP facility on site.
As a clinician-scientist currently leading several cancer clinical trials based on her lab’s pre-clinical research, Dr Auer has a proven ability to translate findings from the bench to the bedside and is committed to improving outcomes for cancer patients and their families.

 

Qualifications:

 

For PDF applicants:

  • PhD degree awarded within the past 1-2 years
  • Demonstrated experience working with animal models of cancer
  • A strong understanding of cancer immunology represented by a track record of presenting and publishing research findings
  • Previous experience with multi-colour flow cytometry, immune cell isolation and functional assays
  • A desire to work as a member of a team and to supervise junior research staff

 

For PhD applicants:

  • Previous practical experience in a research lab environment ideally gained through completion of an MSc
  • Effective written and verbal communication skills
  • A strong academic standing in previous undergraduate/graduate coursework
  • An interest in pursuing a career in cancer immunotherapy

 

Qualifications:

 

PDF and PhD candidates should submit a brief description of their previous research experience including publications along with a CV and contact information for three references to Michael Kennedy via email (mikennedy@ohri.ca).

 

Ottawa Hospital Research Institute

 

Postdoctoral Research Fellow

 

Position: Postdoctoral Research Fellow
Site: Ottawa Hospital Research Institute
Department: Cancer Therapeutics
Hours: 40 Hours per Week

 

Dr. John Bell, in collaboration with Dr. Natasha Kekre and Dr. Harold Atkins, are looking for a highly motivated and detail oriented PhD who aims to develop an independent research career. The candidate will be working on projects involving in vitro and in vivo models of infected cell vaccines for the treatment of acute leukemia.

 

Summary of Research Program:
 

Patients with acute leukemia need more ammunition against their disease, and we propose that a personalized strategy with an oncolytic virus-infected leukemia cell vaccine can offer just that. This vaccine strategy combines cancer-killing viruses with the added ability to stimulate the patient’s own immune system against his/her leukemia. This strategy would provide patients with a less toxic and more personalized approach to defeating leukemia. We have discovered that infected cell vaccines can produce a specific immune response against leukemia, but more work is needed before this can reach clinical trial. This project will test the effect of chemotherapy on the infected cell vaccine response while further experiments will determine the ideal manufacturing and storage conditions needed for an effective vaccine. Completion of this project will create the foundation for further studies that will ultimately bring this new approach for the treatment of leukemia towards a clinical trial.

 

This project is a collaboration with Dr. John Bell, a leader in the field of OV immunotherapy and Chief Scientific Officer of Turnstone Biologics, developing the Maraba virus platform. It is funded by two large program project grants, including an enabling grant designed to ensure that this therapy is optimized (including GMP manufacturing) for early phase clinical trials within 36 months. The lab has access to cancer surgical specimens and a GMP facility on site.
As a clinician-scientist currently leading several cancer clinical trials based on her lab’s pre-clinical research, Dr Auer has a proven ability to translate findings from the bench to the bedside and is committed to improving outcomes for cancer patients and their families.

 

Objectives of Research Program:

  • Complete a robust pre-clinical package that includes safety and efficacy (through immunogenicity and survival data) of the infected cell vaccine under immune compromising conditions.
  • Determine the immune pathways implicated in this infected cell vaccine platform.
  • Based on immune studies, develop a potency assay that will be validated with patient-derived samples, to allow straightforward process design procedure for development of this GLP assay.
  • Understand the key methods and parameters for manufacturing the vaccine including processing of cells, infection with the MG1 virus, irradiation, storage and administration.

 

Qualifications:

  • PhD degree awarded within the past 5 years
  • Solid experience with in vivo animal models and cell culture
  • Hands-on experience in flow cytometry and confocal imaging preferred
  • Hands-on experience with Elispot and ICS preferred
  • Excellent problem recognition and problem-solving skills
  • Excellent verbal and written communication skills
  • Ability to work independently and accurately under stressful conditions
  • Ability to work effectively as a team member
  • Ability to supervise Masters and MD students

 

Interested candidates should submit their CV including names and contact information of three references and a brief description of their research experience and career goals (1 page). To Dr. Natasha Kekre via email at nkekre@toh.ca.